Who benefits most from adjuvant interferon treatment for melanoma?

Helen Gogas*, Huseyin Abali, Paolo A. Ascierto, Lev Demidov, Hubert Pehamberger, Caroline Robert, Jacob Schachter, Alexander M.M. Eggermont, Axel Hauschild, Enrique Espinosa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Metastatic melanoma has a poor prognosis; the median survival for patients with stage IV melanoma ranges from 8 to 18 months after diagnosis. Interferon-α provides significant improvement in disease-free survival at the cost of poor tolerability. Identifying patients who benefit the most may improve the cost:benefit ratio. In addition, no data exist for the role of adjuvant therapy in noncutaneous melanoma. Molecular profiles may help to identify patients who benefit the most from adjuvant interferon therapy. In this review, the American Joint Commission on Cancer 2009 staging criteria and emerging biomarker data to guide adjuvant treatment decisions will be discussed. Several criteria to guide selection of patients are discussed in detail. These include Breslow thickness, number of positive lymph nodes, whether or not the primary lesion has ulcerated, immunologic markers, and cytokine profiles. Substantial progress has been made in deciding which patients benefit from interferon-α adjuvant therapy. Interferon-α is the only agent currently approved for the adjuvant treatment of this deadly disease, despite its side effect profile. More effective drugs with better tolerability are needed.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalAmerican Journal of Therapeutics
Issue number1
StatePublished - 21 Jan 2015
Externally publishedYes


  • Adjuvant treatment
  • interferon-a
  • melanoma
  • selection of patients


Dive into the research topics of 'Who benefits most from adjuvant interferon treatment for melanoma?'. Together they form a unique fingerprint.

Cite this